Biomedical subjects
Alan I Leshner
Publications and source records attributed to Alan I Leshner.
Advancing the frontiers.
Explore the source record for details and available documents.
Redefining science.
Explore the source record for details and available documents.
Where science meets society.
Explore the source record for details and available documents.
A dangerous signal to science.
Explore the source record for details and available documents.
U.S. science dominance is the wrong issue.
Explore the source record for details and available documents.
Science at the leading edge.
Explore the source record for details and available documents.
Ethical issues in taking neuroscience research from bench to bedside.
Dramatic advances in neuroscience have created fast-rising expectations for improvements in the health and well-being of people around the world. But fulfilling this promise is proving to be neither quick nor easy, and not for scientific reasons alone. Alan Leshner urges that neuroscientists not only address the significant challenges of their own investigations but also be willing to participate in ethical and legal dialogues with colleagues and non-colleagues alike.
Don't let ideology trump science.
Explore the source record for details and available documents.
Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
Explore the source record for details and available documents.
Public engagement with science.
Explore the source record for details and available documents.
Advancing science, serving society.
Explore the source record for details and available documents.
What should the public be told about the risks of ecstasy?
Explore the source record for details and available documents.
Putting drug abuse research to use in real-life settings.
Explore the source record for details and available documents.
Experimental and clinical psychopharmacology: National Institute on Drug Abuse's clinical research agenda.
Studies of drugs and behavior are a core component of virtually every portfolio within the broad purview of the National Institute on Drug Abuse (NIDA). Moreover, psychopharmacological research is an important vehicle for advancing understanding of how drugs of abuse produce their effects, particularly including addiction. However, as with all major public health issues, simply understanding the issue is not enough. NIDA's psychopharmacology projects, therefore, span basic, clinical, and applied (e.g., medication development) research activities. These include the establishment of a nationwide clinical trials network designed to provide an infrastructure to test both behavioral and psychopharmacological treatments in a real-life practice setting with diverse patients.
Science-based views of drug abuse and addiction.
Explore the source record for details and available documents.
Ecstasy abuse and control: hearing before the Senate Subcommittee on Governmental Affairs--July 30, 2001. Statement for the record.
Explore the source record for details and available documents.
It's time to go public with neuroethics.
Explore the source record for details and available documents.